YONKERS, N.Y., March 21, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated biologic therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Cara Cassino, M.D., Chief Medical Officer and Executive Vice President of Research and Development will participate in the inaugural Bacteriophage Therapy Summit (“Summit”) to be held from March 25-27, 2019 in Boston, MA. Dr. Cassino was invited to the Summit to present ContraFect’s journey to positive results in its Phase 2 clinical study with the first non-traditional antibacterial to progress to this stage of development. She will be joined by large pharmaceutical and biotech companies, research institutions and technology experts, in their efforts to accelerate the clinical development of non-traditional products such as phage and phage-derived therapies.
Dr. Cassino will discuss the path ContraFect forged to progress exebacase, its first-in-class, phage-derived lysin, from the laboratory through a novel, superiority design Phase 2 study, the first clinical trial of its kind in antibacterials.
Title: The Pathway from Bench to Bedside: Lysin CF-301 (exebacase) – A Case Study
Session Day & Time: Wednesday, March 27, 2019, 1:30 p.m. – 2:00 p.m. ET
Topics to be discussed include:
- Harnessing potent in vitro activity to address unmet medical need
- Adapting traditional antibiotic development models to non-traditional antibacterials
- Exploring the challenges and opportunities of superiority studies – novel antibacterials warrant a novel clinical development approach
ContraFect is a biotechnology company focused on discovering and developing differentiated biologic therapeutics for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our lysin platform and through the use of other novel agents. Lysins are a new therapeutic class of bacteriophage-derived, recombinantly produced, antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. We believe that the properties of our lysins will make them suitable for targeting antibiotic-resistant organisms, such as Staphylococcus aureus (“Staph aureus”) and Pseudomonas aeruginosa (“P. aeruginosa”), which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. Our lead lysin candidate, exebacase (CF-301) is completing a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis and is the first lysin to enter clinical studies in the U.S.
This press release contains, and our officers and representatives may make from time to time, “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding the Company’s ability to discover and develop novel, differentiated biologic therapeutics for life-threatening, drug-resistant infectious diseases, statements made regarding the Summit, including presentation details, and ContraFect’s Phase 2 results, whether the Company has the first non-traditional antibacterial to progress to this stage of development, whether the Phase 2 study design was novel and the first of its kind in antibacterials, the Company’s ability to address life threatening infections using its therapeutic product candidates from its lysin platform and through the use of other novel agents, whether lysins are a new therapeutic class of bacteriophage-derived, recombinantly produced, antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics and whether the properties of the Company’s lysins will make them suitable for targeting antibiotic-resistant organisms, such as Staph aureus and P. aeruginosa. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect’s current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect’s control, including those detailed in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.